EUVIMEDAtrasti EUVIMED
CrossrefInformacijos kortelė

A real-world study of diverse RC48-based regimens across disease stages of urothelial carcinoma

Liangliang Qing, Lingyi Li, Qingchao Li, Yongjin Yang, Wenbo Xu, Yanan Wang, Rongxing Li, Chengyu You, Zhilong Dong

Bladder · 2025

DOI: 10.14440/bladder.0169 ↗
SantraukaBibliografiniai duomenys

Santrauka

Background: RC48, a human epidermal growth factor receptor 2 (HER2)-targeting antibody–drug conjugate (ADC), has been approved in China for the treatment of HER2-positive metastatic urothelial carcinoma. Objective: This study evaluated the efficacy and safety of various RC48-based regimens in patients with urothelial carcinoma across disease stages in real-world settings. Methods: We retrospectively analyzed data from 56 patients at different disease stages who were treated at the Second Hospital of Lanzhou University between March 2023 and June 2024. RC48-ADC was administered as a monotherapy or in combination with immunotherapy until discontinuation due to disease progression, intolerable toxicity, death, or other reasons. Results: Outcomes included the objective response rate (ORR), progression-free survival (PFS), overall survival (OS), and treatment-related adverse events (TRAEs). The median patient age was 67.5 years, with 83.9% being male. Of all patients, 14 (25.0%) received RC48-ADC monotherapy, and 42 (75.0%) received RC48-ADC combined with immunotherapy. Response rates were as follows: 15 patients (26.8%) achieved complete remission, 21 (37.5%) attained partial remission, 14 (25.0%) had stable disease, and 6 (10.7%) suffered from disease progression. The overall ORR was 64.3%, with rates of 70.0% and 60.0% in first-line and second-line treatment groups, respectively. The median PFS lasted for 6 months (range: 5–7 months), whereas the median OS was not reached. The most common TRAEs were peripheral sensory neuropathy (58.9%), fatigue (48.2%), decreased appetite (42.9%), and weight loss (37.5%). Conclusion: No increased incidence of TRAEs was observed in patients with poor performance status or impaired kidney function. RC48-ADC demonstrated efficacy and safety in patients with urothelial carcinoma, providing clinical benefits regardless of performance status or renal function.

Jūsų darbui tinkamos žinios.

Nuo nemokamos pradžios ir asmeninės literatūros paieškos iki viso Research Suite.

Peržiūrėti tarifus →

Ar įtraukti visi leidėjų pilnieji tekstai?

Ne. Bibliografiniai įrašai, santraukos ir pilnieji tekstai yra skirtingas turinys. Ar pilnasis tekstas prieinamas, priklauso nuo šaltinio, Open Access ir jūsų turimų licencijų. EUVIMED planas nepakeičia papildomų leidėjų teisių.

Peržiūrėti tarifus →